Kidney Disease Management

Introduction to Kidney Function Assessment

• Serum creatinine alone is an inadequate measure of kidney function, as it may remain "normal" despite significant kidney dysfunction, especially in elderly or those with reduced muscle mass, according to the American College of Physicians 1
• Calculate eGFR using validated equations (e.g., MDRD or CKD-EPI) that account for age, sex, race, and body size, as recommended by the National Kidney Foundation 1, 2
• Normal eGFR values are defined as ≥90 mL/min/1.73 m², mildly decreased as 60-89 mL/min/1.73 m², moderately decreased as 30-59 mL/min/1.73 m² (Stage 3 CKD), severely decreased as 15-29 mL/min/1.73 m² (Stage 4 CKD), and kidney failure as <15 mL/min/1.73 m² (Stage 5 CKD) 2
• Clinical laboratories should report eGFR with serum creatinine measurements 1

Patient Assessment and Monitoring

• Monitor both creatinine and eGFR in patients, especially those at risk for kidney disease, as small changes in serum creatinine can represent significant changes in kidney function, particularly in elderly patients or those with reduced muscle mass 1
• Evaluate for risk factors and causes, including medications (NSAIDs, aminoglycosides, contrast media), volume depletion, urinary tract obstruction, underlying chronic conditions (diabetes, hypertension), and recent procedures involving contrast media, as recommended by the American College of Physicians 1
• For patients with cirrhosis, close monitoring of creatinine levels is required as it may progress to hepatorenal syndrome, with a target creatinine level of <1.5 mg/dL, according to the American Association for the Study of Liver Diseases 3
• In patients on immune checkpoint inhibitors, monitor creatinine before every dose, with a recommended frequency of at least every 2 weeks, as suggested by the Society for Immunotherapy of Cancer 4
• The American College of Cardiology recommends optimizing blood pressure control to a target of <130/85 mmHg to slow progression of kidney disease 5
• Medication monitoring should include checking creatinine and potassium within 7 days of initiating medications that affect kidney function (e.g., ACE inhibitors, ARBs, aldosterone antagonists), as recommended by guidelines that align with the principles of the American College of Cardiology 6

Management of Acute Kidney Injury

• If AKI is suspected, hold potentially nephrotoxic medications, evaluate for pre-renal causes, and assess for post-renal obstruction with ultrasound if clinically indicated, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 7
• In patients with AKI, monitor urine output and daily creatinine, with a target urine output of >0.5 mL/kg/h, according to the KDIGO guidelines 7
• A creatinine level of 1.23 mg/dL may represent Stage 1 Acute Kidney Injury or early Chronic Kidney Disease, requiring additional assessment of kidney function through eGFR calculation and clinical context, according to the American College of Physicians and the National Kidney Foundation 1
• Even small increases in creatinine can indicate significant kidney injury, with a rise of ≥0.3 mg/dL within 48 hours indicating Stage 1 Acute Kidney Injury 8
• Any creatinine elevation during hospitalization for conditions like heart failure is associated with increased mortality, highlighting the importance of monitoring kidney function in high-risk populations 9, 6

Management of Chronic Kidney Disease

• If CKD is suspected, implement measures to slow progression, such as blood pressure control and diabetes management, and consider nephrology referral if eGFR <60 mL/min/1.73m², as recommended by the National Kidney Foundation 5
• Screen for complications of CKD, such as anemia and mineral bone disease, with a recommended frequency of at least every 6 months, according to the National Kidney Foundation 5
• In hypertensive patients, target BP should be <130/85 mmHg in patients with elevated creatinine, as recommended by the American Heart Association 10
• In patients receiving immunotherapy, a creatinine level of 1.23 mg/dL represents Grade 1 nephritis if it's an increase of >0.3 mg/dL from baseline, and may require temporary holding of immune checkpoint inhibitors and monitoring, as stated by the Society for Immunotherapy of Cancer 4, 11
• In cirrhosis patients, creatinine >1.2 mg/dL is associated with worse outcomes and may require intervention, including consideration for vasoconstrictor therapy if it increases to >1.5 mg/dL (Stage 1b AKI), as recommended by the American Association for the Study of Liver Diseases 3

2